Forest Labs FY13 guidance likely to below consensus, says Goldman at Goldman

Goldman expects Forest Labs to have an in-line Q4 report but for FY13 guidance to be below consensus. The firm continues to see downside ris to key growth assets and does not expect Lexapro to provide support. Shares are Sell rated with a $31 price target, up from $30.

View Comments (0)